NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nanoscope Therapeutics Inc.

Nanoscope Therapeutics Inc.

Private
Dallas, TexasHealthcare & Life Scienceshttps://nanostherapeutics.com/

Last Round

Grant

Sep 14, 2021

Total Funding Raised

$14.83M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nanoscope Therapeutics Inc. is a biotechnology company developing gene-agnostic, vision-restoring optogenetic therapies for patients blinded by retinal degenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyoptogeneticseye gene therapyretinal degenerative diseasevision restorationinherited retinal diseaseintravitreal injectionblindness cureretinitis pigmentosaStargardt diseasebiotechregenerative medicineclinical-stage biotechophthalmologyRMAT designationBLA filing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanoscope Therapeutics Inc. Comparables

Compare Nanoscope Therapeutics Inc. with similar companies based on industry and business-model similarity.

Nanoscope Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ray Therapeutics
86%
SparingVision
85%
Gensight Biologics
84%

Nanoscope Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 14, 2021
Series AJul 21, 2020
GrantJun 22, 2020

Key People

Founding team and executive leadership

Michael Marquez

CFO

Executive Team

Nanoscope Therapeutics Inc. Investors

Notable investors and investment history

Nanoscope Therapeutics Inc. investors
InvestorRounds
NIH RADxGrant
AG Collective CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Attending ARVO 2026 Annual Meeting and Eyecelerator @ ARVO 2026.

  • Mar 23, 2026

    Developing MCO-010, a one-time optogenetic therapy for retinal diseases.

Nanoscope Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nanoscope Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nanoscope Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersDallas, Texas
Employee Range47
Year Founded2017
Last FundingSep 14, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.